Incyte (NASDAQ:INCY) Releases Earnings Results, Beats Estimates By $0.89 EPS

Posted by Geri Gentry on Jul 28th, 2026

Incyte (NASDAQ:INCY – Get Free Report) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported $3.09 EPS for the quarter, topping the consensus estimate of $2.20 by $0.89, FiscalAI reports. Incyte had a net margin of 26.71% and a return on equity of 26.66%. The firm had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.50 billion.

Incyte Trading Up 1.0%

NASDAQ:INCY opened at $118.87 on Tuesday. The stock has a market cap of $23.75 billion, a price-to-earnings ratio of 16.79, a price-to-earnings-growth ratio of 1.06 and a beta of 0.76. Incyte has a one year low of $69.69 and a one year high of $120.71. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.60 and a current ratio of 3.68. The business’s 50-day simple moving average is $107.30 and its 200 day simple moving average is $101.72.

Hedge Funds Weigh In On Incyte

Institutional investors and hedge funds have recently made changes to their positions in the business. Jacobi Capital Management LLC grew its position in shares of Incyte by 0.9% during the fourth quarter. Jacobi Capital Management LLC now owns 10,613 shares of the biopharmaceutical company’s stock worth $1,048,000 after buying an additional 99 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in Incyte by 7.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,628 shares of the biopharmaceutical company’s stock valued at $161,000 after acquiring an additional 113 shares in the last quarter. Bank of Nova Scotia raised its holdings in Incyte by 0.7% in the second quarter. Bank of Nova Scotia now owns 17,041 shares of the biopharmaceutical company’s stock valued at $1,160,000 after acquiring an additional 124 shares in the last quarter. Perbak Capital Partners LLP raised its holdings in Incyte by 2.5% in the third quarter. Perbak Capital Partners LLP now owns 5,298 shares of the biopharmaceutical company’s stock valued at $449,000 after acquiring an additional 129 shares in the last quarter. Finally, QTR Family Wealth LLC boosted its stake in Incyte by 3.7% during the 4th quarter. QTR Family Wealth LLC now owns 3,730 shares of the biopharmaceutical company’s stock valued at $373,000 after acquiring an additional 133 shares during the last quarter. 96.97% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on INCY shares. HC Wainwright reaffirmed a “buy” rating and issued a $140.00 price objective on shares of Incyte in a research note on Tuesday, July 21st. TD Cowen reiterated a “hold” rating on shares of Incyte in a report on Tuesday, June 9th. Barclays boosted their price target on Incyte from $117.00 to $134.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 14th. Morgan Stanley upped their price target on Incyte from $103.00 to $104.00 and gave the stock an “equal weight” rating in a report on Thursday. Finally, Citigroup reaffirmed a “market perform” rating on shares of Incyte in a research report on Wednesday, July 15th. Eight investment analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $111.10.

Read Our Latest Analysis on INCY

About Incyte

(Get Free Report)

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.